# A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

> **NCT05662670** · PHASE1,PHASE2 · TERMINATED · sponsor: **Suzhou Junjing BioSciences Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Locally Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** WJ13404 tablets

## Key facts

- **NCT ID:** NCT05662670
- **Lead sponsor:** Suzhou Junjing BioSciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-11
- **Primary completion:** 2023-10-01
- **Final completion:** 2024-04-09
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Due to the adjustment of the R\&D strategy, Suzhou Junjing Biosciences Co., Ltd. decided to terminate this study in September 2023
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662670, "A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05662670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*